Advertisement

Current Atherosclerosis Reports

, Volume 9, Issue 2, pp 125–133 | Cite as

The role of CETP inhibition in dyslipidemia

  • Karim El Harchaoui
  • Wim A. van der Steeg
  • Erik S. G. Stroes
  • John J. P. Kastelein
Open Access
Article

Abstract

Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceriderich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors.

Keywords

Atorvastatin Cholesteryl Ester Transfer Protein Familial Hypercholesterolemia Arterioscler Thromb Vasc Biol Torcetrapib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Doggrell SA: Inhibitors of cholesteryl ester transfer protein—a new approach to coronary artery disease. Exp Opin Invest Drugs 2006, 15:99–106.CrossRefGoogle Scholar
  2. 2.
    Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185–197.PubMedCrossRefGoogle Scholar
  3. 3.
    Curb JD, Abbott RD, Rodriguez BL, et al.: A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004, 45:948–953.PubMedCrossRefGoogle Scholar
  4. 4.
    Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al.: Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the Prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study. Circulation 2004, 110:1418–1423.PubMedCrossRefGoogle Scholar
  5. 5.
    de Grooth GJ, Smilde TJ, van Wissen S, et al.: The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004, 173:261–267.PubMedCrossRefGoogle Scholar
  6. 6.
    de Vries R, Perton FG, Linga-Thie GM, et al.: Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of cetp and triglycerides. Diabetes 2005, 54:3554–3559.PubMedCrossRefGoogle Scholar
  7. 7.
    Sikorski JA: Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease. J Med Chem 2006, 49:1–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Nishida HI, Arai H, Nishida T: Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins. J Biol Chem 1993, 268:16352–16360.PubMedGoogle Scholar
  9. 9.
    Le Goff W, Guerin M, Chapman MJ: Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 2004, 101:17–38.PubMedCrossRefGoogle Scholar
  10. 10.
    Barter PJ, Brewer HB Jr, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160–167.PubMedCrossRefGoogle Scholar
  11. 11.
    Borggreve SE, de Vries R, Dullaart RP: Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003, 33:1051–1069.PubMedCrossRefGoogle Scholar
  12. 12.
    Tato F, Vega GL, Grundy SM: Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients: role of cholesterol-ester transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Thromb Vasc Biol 1997, 17:56–63.PubMedGoogle Scholar
  13. 13.
    Mann CJ, Yen FT, Grant AM, Bihain BE: Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991, 88:2059–2066.PubMedGoogle Scholar
  14. 14.
    Kontush A, Chapman MJ: Antiatherogenic small, dense HDL—guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006, 3:144–153.PubMedCrossRefGoogle Scholar
  15. 15.
    Venkatesan S, Cullen P, Pacy P, et al.: Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 1993, 13:1110–1118.PubMedGoogle Scholar
  16. 16.
    Tato F, Vega GL, Tall AR, Grundy SM: Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1995, 15:112–120.PubMedGoogle Scholar
  17. 17.
    Vakkilainen J, Jauhiainen M, Ylitalo K, et al.: LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 2002, 43:598–603.PubMedGoogle Scholar
  18. 18.
    Davidson MH, McKenney JM, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 2006, 48:1774–1781.PubMedCrossRefGoogle Scholar
  19. 19.
    Arai T, Yamashita S, Hirano K, et al.: Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994, 14:1129–1136.PubMedGoogle Scholar
  20. 20.
    Ebenbichler CF, Laimer M, Kaser S, et al.: Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women. Arterioscler Thromb Vasc Biol 2002, 22:1465–1469.PubMedCrossRefGoogle Scholar
  21. 21.
    Sandhofer A, Kaser S, Ritsch A, et al.: Cholesteryl ester transfer protein in metabolic syndrome. Obesity 2006, 14:812–818.PubMedGoogle Scholar
  22. 22.
    Quintao EC, Medina WL, Passarelli M: Reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 2000, 16:237–250.PubMedCrossRefGoogle Scholar
  23. 23.
    Passarelli M, Catanozi S, Nakandakare ER, et al.: Plasma lipoproteins from patients with poorly controlled diabetes mellitus and “in vitro” glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins. Diabetologia 1997, 40:1085–1093.PubMedCrossRefGoogle Scholar
  24. 24.
    Lahdenpera S, Syvanne M, Kahri J, Taskinen MR: Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 1996, 39:453–461.PubMedCrossRefGoogle Scholar
  25. 25.
    Jansen AC, van Aalst-Cohen ES, Tanck MW, et al.: The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004, 256:482–490.PubMedCrossRefGoogle Scholar
  26. 26.
    Bagdade JD, Ritter MC, Subbaiah PV: Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia. J Clin Invest 1991, 87:1259–1265.PubMedCrossRefGoogle Scholar
  27. 27.
    Hannuksela M, Marcel YL, Kesaniemi YA, Savolainen MJ: Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 1992, 33:737–744.PubMedGoogle Scholar
  28. 28.
    Seip RL, Moulin P, Cocke T, et al.: Exercise training decreases plasma cholesteryl ester transfer protein. Arterioscler Thromb 1993, 13:1359–1367.PubMedGoogle Scholar
  29. 29.
    Dullaart RP, Hoogenberg K, Dikkeschei BD, van Juvy TA: Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 1994, 14:1581–1585.PubMedGoogle Scholar
  30. 30.
    Lewis-Barned NJ, Sutherland WH, Walker RJ, et al.: Plasma cholesterol esterification and transfer, the menopause, and hormone replacement therapy in women. J Clin Endocrinol Metab 1999, 84:3534–3538.PubMedCrossRefGoogle Scholar
  31. 31.
    Ahnadi CE, Berthezene F, Ponsin G: Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 1993, 99:219–228.PubMedCrossRefGoogle Scholar
  32. 32.
    van Wijk JP, Buirma R, van Tol A, et al.: Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis 2005, 178:147–155.PubMedCrossRefGoogle Scholar
  33. 33.
    Le NA, Innis-Whitehouse W, Li X, et al.: Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 2000, 49:167–177.PubMedCrossRefGoogle Scholar
  34. 34.
    Guerin M, Lassel TS, Le Goff W, et al.: Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000, 20:189–197.PubMedGoogle Scholar
  35. 35.
    Kassai A, Illyes L, Mirdamadi HZ, et al.: The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem 2006, In press.Google Scholar
  36. 36.
    Guerin M, Dolphin PJ, Talussot C, et al.: Pravastatin modulates cholesteryl ester transfer from hdl to apob-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995, 15:1359–1368.PubMedGoogle Scholar
  37. 37.
    Bhatnagar D, Durrington PN, Kumar S, et al.: Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 1995, 44:460–465.PubMedCrossRefGoogle Scholar
  38. 38.
    Klerkx AH, de Grooth GJ, Zwinderman AH, et al.: Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004, 34:21–28.PubMedCrossRefGoogle Scholar
  39. 39.
    Marschang P, Sandhofer A, Ritsch A, et al.: Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med 2006, 260:151–159.PubMedCrossRefGoogle Scholar
  40. 40.
    Durrington PN, Mackness MI, Bhatnagar D, et al.: Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998, 138:217–225.PubMedCrossRefGoogle Scholar
  41. 41.
    Guerin M, Bruckert E, Dolphin PJ, et al.: Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL Profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996, 16:763–772.PubMedGoogle Scholar
  42. 42.
    Watts GF, Ji J, Chan DC, et al.: Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clin Sci (London) 2006, 111:193–199.Google Scholar
  43. 43.
    Franceschini G, Lovati MR, Manzoni C, et al.: Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis 1995, 114:61–71.PubMedCrossRefGoogle Scholar
  44. 44.
    Ponsin G, Girardot G, Berthezene F: Mechanism of the gemfibrozil-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins. Biochem Med Metab Biol 1994, 52:58–64.PubMedCrossRefGoogle Scholar
  45. 45.
    de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002, 105:2159–2165.PubMedCrossRefGoogle Scholar
  46. 46.
    Kuivenhoven JA, de Grooth GJ, Kawamura H, et al.: Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005, 95:1085–1088.PubMedCrossRefGoogle Scholar
  47. 47.
    Bisoendial RJ, Hovingh GK, El HK, et al.: Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 2005, 25:e133–e134.PubMedCrossRefGoogle Scholar
  48. 48.
    Clark RW, Sutfin TA, Ruggeri RB, et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004, 24:490–497.PubMedCrossRefGoogle Scholar
  49. 49.
    Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505–1515.PubMedCrossRefGoogle Scholar
  50. 50.
    McKenney JM, Davidson MH, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006, 48:1782–1790.PubMedCrossRefGoogle Scholar
  51. 51.
    Matsuura F, Wang N, Chen W, et al.: HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE-and ABCG1-dependent pathway. J Clin Invest 2006, 116:1435–1442.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Karim El Harchaoui
    • 1
  • Wim A. van der Steeg
  • Erik S. G. Stroes
  • John J. P. Kastelein
  1. 1.Department of Vascular Medicine, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations